What is Bioniq?
Bioniq operates at the intersection of health technology and artificial intelligence, offering bespoke nutritional solutions derived from individual blood test data. This innovative approach positions the company as a leader in the burgeoning personalized wellness sector, leveraging AI to tailor supplement recommendations for optimal health outcomes. The company's launch in 2019 marked the beginning of its mission to revolutionize the supplement industry through data-driven personalization.
How much funding has Bioniq raised?
Bioniq has raised a total of $22.8M across 2 funding rounds:
Series A
$7.8M
Series B
$15M
Series A (2021): $7.8M with participation from OKS Group incorporated
Series B (2024): $15M led by Unbound and HV Capital
Key Investors in Bioniq
Unbound
Unbound is an investor participating in the funding round, likely focusing on innovative health and wellness ventures.
HV Capital
HV Capital is a venture funding firm that invests in companies in the early stages of business, with offices in Munich and Berlin, Germany.
OKS Group incorporated
OKS Group incorporated is an investor that participated in Bioniq's Series A funding round.
What's next for Bioniq?
With its recent Series B financing, Bioniq is poised for significant expansion. This capital infusion is expected to fuel further development of its AI platform, enhance its product offerings, and broaden its market reach. The strategic investment signals strong investor confidence in Bioniq's business model and its potential to disrupt the traditional supplement market, paving the way for accelerated growth and innovation in personalized health.
See full Bioniq company page
